The One-Line Clinical Answer
In every major clinical trial, the NewSelf program's tirzepatide produces greater average weight loss than semaglutide. But average outcomes don't determine individual decisions — your health profile, budget, and physician guidance matter equally.
| Dimension | Semaglutide Plus⁺ | Tirzepatide Plus⁺ |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg. weight loss | ~15% (STEP-1) | ~22.5% (SURMOUNT-1, max dose) |
| NewSelf price | $99.97/mo | $144.49/mo |
| Vitamin blend | B12 or Glycine | B6 or Glycine |
| Dosages | 0.25–2.5mg | 2.5–15mg |
⚡ Limited Time: Free Overnight Shipping
Choose your medication and start with NewSelf's compounded GLP-1 today. Both options available at flat pricing — all dosages same price.
✓ All dosages same price · ✓ Full refund if declined · ✓ No membership fees
STEP-1 vs SURMOUNT-1
STEP-1 (NEJM, 2021): semaglutide 2.4mg — 14.9% average body weight loss over 68 weeks; 86.4% achieved ≥5% loss. SURMOUNT-1 (NEJM, 2022): tirzepatide 15mg — 22.5% average weight loss over 72 weeks; 57% achieved ≥20% loss — previously achievable only with bariatric surgery. In JAMA Internal Medicine (2023), tirzepatide outperformed semaglutide at every dose across all BMI categories in real-world analysis over 12 months.
Which Should You Choose at NewSelf?
For maximum weight loss with no budget constraint: Tirzepatide Plus⁺ $144.49/mo. The $44.52 premium is justified by meaningfully superior outcomes. For proven first-line GLP-1 at the lowest available market price: Semaglutide Plus⁺ $99.97/mo. Both are clinically excellent at the NewSelf platform's flat-rate pricing. Your physician determines which is medically appropriate for your specific profile. See the full guide: semaglutide vs tirzepatide comparison.